Stavropoulos A, Filippou D
Croat Med J. 2025; 65(6):510-517.
PMID: 39812100
PMC: 11748445.
Yang C, He Y, Yuan L, Yuan C, Chang F, Feng W
Brain Behav Immun Health. 2024; 39:100803.
PMID: 39022626
PMC: 466972.
DOI: 10.1016/j.bbih.2024.100803.
Pandey S, Bapat V, Abraham J, Abraham N
World J Otorhinolaryngol Head Neck Surg. 2024; 10(2):137-147.
PMID: 38855289
PMC: 11156689.
DOI: 10.1002/wjo2.175.
Renukaprasad A, Basu Roy P, Rao A
IDCases. 2024; 36:e01982.
PMID: 38765801
PMC: 11101951.
DOI: 10.1016/j.idcr.2024.e01982.
Hameed R, Bahadur A, Singh S, Sher J, Todua M, Moradi L
Diagnostics (Basel). 2023; 13(14).
PMID: 37510097
PMC: 10378471.
DOI: 10.3390/diagnostics13142353.
Interaction between COVID-19 and epilepsy during the omicron surge: A cross-sectional survey conducted in China tertiary hospital.
Li X, Sun S, Yan C, Liu X
Epilepsy Behav Rep. 2023; 23:100613.
PMID: 37501889
PMC: 10368756.
DOI: 10.1016/j.ebr.2023.100613.
Post-COVID-19 Syndrome Mechanisms, Prevention and Management.
Najafi M, Javanmard S
Int J Prev Med. 2023; 14:59.
PMID: 37351054
PMC: 10284243.
DOI: 10.4103/ijpvm.ijpvm_508_21.
Acute arthritis following SARS-CoV-2 infection: About two cases.
Brahem M, Jomaa O, Arfa S, Sarraj R, Tekaya R, Berriche O
Clin Case Rep. 2023; 11(5):e7334.
PMID: 37205154
PMC: 10185734.
DOI: 10.1002/ccr3.7334.
Effect of fluvoxamine on preventing neuropsychiatric symptoms of post COVID syndrome in mild to moderate patients, a randomized placebo-controlled double-blind clinical trial.
Farahani R, Ajam A, Naeini A
BMC Infect Dis. 2023; 23(1):197.
PMID: 37003990
PMC: 10064948.
DOI: 10.1186/s12879-023-08172-5.
Late neurological consequences of SARS-CoV-2 infection: New challenges for the neurologist.
Korchut A, Rejdak K
Front Neurosci. 2023; 17:1004957.
PMID: 36845421
PMC: 9947479.
DOI: 10.3389/fnins.2023.1004957.
Epilepsy and COVID 2021.
Valencia I, Berg A, Hirsch L, Lopez M, Melmed K, Rosengard J
Epilepsy Curr. 2022; 22(6):398-403.
PMID: 36426190
PMC: 9661620.
DOI: 10.1177/15357597221101268.
Issues related to post-COVID-19 syndrome.
Ozdemir O, Arslan Z
World J Methodol. 2022; 12(4):224-234.
PMID: 36159103
PMC: 9350724.
DOI: 10.5662/wjm.v12.i4.224.
Effects of vaccination, new SARS-CoV-2 variants and reinfections on post-COVID-19 complications.
Orendacova M, Kvasnak E
Front Public Health. 2022; 10:903568.
PMID: 35968477
PMC: 9372538.
DOI: 10.3389/fpubh.2022.903568.
Effect of neurofeedback therapy on neurological post-COVID-19 complications (A pilot study).
Orendacova M, Kvasnak E, Vranova J
PLoS One. 2022; 17(7):e0271350.
PMID: 35895740
PMC: 9328527.
DOI: 10.1371/journal.pone.0271350.
Status epilepticus due to COVID-19; a cases series and literature review.
Kheradmand M, Hemasian H, Khorvash F, Najafi M, Ghadimi K, Forouharnejad K
Am J Neurodegener Dis. 2022; 11(2):34-45.
PMID: 35874940
PMC: 9301094.
Neurological manifestations of post-COVID-19 syndrome S1-guideline of the German society of neurology.
Franke C, Berlit P, Pruss H
Neurol Res Pract. 2022; 4(1):28.
PMID: 35843984
PMC: 9288923.
DOI: 10.1186/s42466-022-00191-y.
Persistent neurological manifestations in long COVID-19 syndrome: A systematic review and meta-analysis.
Pinzon R, Wijaya V, Jody A, Nunsio P, Buana R
J Infect Public Health. 2022; 15(8):856-869.
PMID: 35785594
PMC: 9221935.
DOI: 10.1016/j.jiph.2022.06.013.
Pneumonia in Nervous System Injuries: An Analytic Review of Literature and Recommendations.
Erfani Z, Mamaghani H, Rawling J, Eajazi A, Deever D, Mirmoeeni S
Cureus. 2022; 14(6):e25616.
PMID: 35784955
PMC: 9249029.
DOI: 10.7759/cureus.25616.
Treatment of COVID-19-induced refractory status epilepticus by tocilizumab.
Kizilkilic E, Unkun R, Uygunoglu U, Delil S, Ozkara C
Eur J Neurol. 2022; 29(9):2861-2863.
PMID: 35678591
PMC: 9348353.
DOI: 10.1111/ene.15440.
COVID-19 2022 update: transition of the pandemic to the endemic phase.
Biancolella M, Colona V, Mehrian-Shai R, Watt J, Luzzatto L, Novelli G
Hum Genomics. 2022; 16(1):19.
PMID: 35650595
PMC: 9156835.
DOI: 10.1186/s40246-022-00392-1.